BackgroundThe Metasul articular interface was a second-generation metal-on-metal (MoM) total hip arthroplasty (THA) that was introduced as a promising interface with improved manufacturing technology, better clearances, and enhanced metal hardness. In December 2001, the manufacturer recalled these implants due to the failure of cup osseointegration. MethodsBetween 1997 and 2004, 168 consecutive primary Metasul THAs were performed in 144 patients. Most patients received a cementless femoral and porous-coated acetabular component with 28 mm head. A competing risk analysis was performed for determination separately for bearing surface-related, recalled bearing failure, and end point revision for any reason. For clinical patient evaluation, we used Harris hip score and University of California at Los Angeles scores. Cobalt and chromium ion level measurement and standard radiographic assessment was performed. ResultsOf the 168 THAs, 19 hips were revised at a mean period of 15 years as follows: 12 of them were due to recalled acetabular component, five hips had noninterface-related complication, and two true interface surface failure. The survival distribution function of all hips with revision for any reason was 88.4%, for bearing interface relation 98.8%, and 92.6% for recalled cups. The mean Harris hip score and University of California at Los Angeles scores were 85 and 6, respectively, and the median Co and Cr blood levels were 1.0 and 0.91 μg/L. ConclusionExcluding the recalled components, Metasul articular interface has performed extremely well at a minimum follow-up of 15 years in this relatively young population. There were two interface-related revisions in the entire cohort.